[{"id":"69c0c3d7-d12e-4846-a87b-98d5f38f2dcd","acronym":"SJDAWN","url":"https://clinicaltrials.gov/study/NCT03434262","created_at":"2021-01-18T16:56:26.116Z","updated_at":"2024-07-02T16:34:59.830Z","phase":"Phase 1","brief_title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","source_id_and_acronym":"NCT03434262 - SJDAWN","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-05-31"},{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2024-07-02T16:35:01.843Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation • CDKN2A mutation • PTCH1 mutation • NF2 mutation • AKT1 mutation • SMO mutation • PIK3CA mutation + PTEN mutation • CDK4 mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation • CDKN2A mutation • PTCH1 mutation • NF2 mutation • AKT1 mutation • SMO mutation • PIK3CA mutation + PTEN mutation • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-23"},{"id":"962a2b73-b00a-476e-82b6-64720adf870e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03467789","created_at":"2021-01-18T17:05:25.626Z","updated_at":"2024-07-02T16:35:06.292Z","phase":"Phase 1","brief_title":"Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma","source_id_and_acronym":"NCT03467789","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-02"},{"id":"ef5ef83b-bc3d-4dc9-9b78-e271828de65e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06050122","created_at":"2023-09-22T14:10:44.436Z","updated_at":"2024-07-02T16:35:08.695Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","source_id_and_acronym":"NCT06050122","lead_sponsor":"Sol-Gel Technologies, Ltd.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (IPI-926 topical)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/17/2024","start_date":" 03/17/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-19"},{"id":"7d881018-0265-4ecb-9d18-1c4241cf9170","acronym":"","url":"https://clinicaltrials.gov/study/NCT05199584","created_at":"2022-01-20T14:53:33.589Z","updated_at":"2024-07-02T16:35:26.000Z","phase":"Phase 2","brief_title":"A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations","source_id_and_acronym":"NCT05199584","lead_sponsor":"Endeavor Biomedicines, Inc.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e taladegib (ENV 101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-12-18"},{"id":"d06e8af1-41a9-44ee-8b8e-7998ed004a25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703310","created_at":"2021-01-18T18:08:53.199Z","updated_at":"2024-07-02T16:36:33.679Z","phase":"Phase 3","brief_title":"Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)","source_id_and_acronym":"NCT03703310","lead_sponsor":"PellePharm, Inc.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (IPI-926 topical)"],"overall_status":"Completed","enrollment":" Enrollment 174","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2021-03-08"},{"id":"bd4e22eb-e007-4bbd-b9f9-de346b73748b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00489086","created_at":"2021-01-18T01:44:50.001Z","updated_at":"2024-07-02T16:36:39.432Z","phase":"Phase 2","brief_title":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face","source_id_and_acronym":"NCT00489086","lead_sponsor":"UCSF Benioff Children's Hospital Oakland","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 07/01/2004","start_date":" 07/01/2004","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2020-10-29"},{"id":"6889e74c-2f8e-4b32-bd6f-76f2558287eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02157623","created_at":"2021-01-18T10:02:07.074Z","updated_at":"2024-07-02T16:36:42.587Z","phase":"","brief_title":"Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome","source_id_and_acronym":"NCT02157623","lead_sponsor":"Edward Maytin, MD, PhD","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2020-07-30"},{"id":"9d1cbdcb-bda6-4638-bfe0-b1a719e61280","acronym":"","url":"https://clinicaltrials.gov/study/NCT02762084","created_at":"2021-01-18T13:32:43.587Z","updated_at":"2024-07-02T16:36:42.846Z","phase":"Phase 2","brief_title":"Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients","source_id_and_acronym":"NCT02762084","lead_sponsor":"PellePharm, Inc.","biomarkers":" PTCH1 • GLI1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1 • GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (IPI-926 topical)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 06/06/2016","start_date":" 06/06/2016","primary_txt":" Primary completion: 04/24/2017","primary_completion_date":" 04/24/2017","study_txt":" Completion: 04/24/2017","study_completion_date":" 04/24/2017","last_update_posted":"2020-07-23"},{"id":"2815f4fd-83a7-4e30-81b4-884c2f6a5954","acronym":"","url":"https://clinicaltrials.gov/study/NCT02258243","created_at":"2021-01-18T10:36:28.725Z","updated_at":"2024-07-02T16:37:27.711Z","phase":"Phase 2","brief_title":"Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome","source_id_and_acronym":"NCT02258243","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2016-11-07"},{"id":"8f16b74c-47d6-443e-9b47-2484b298946e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00783965","created_at":"2021-01-18T02:57:47.324Z","updated_at":"2024-07-02T16:37:34.183Z","phase":"Phase 2","brief_title":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back","source_id_and_acronym":"NCT00783965","lead_sponsor":"UCSF Benioff Children's Hospital Oakland","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 07/01/2004","start_date":" 07/01/2004","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2016-02-11"},{"id":"ea0a476d-0960-43a4-8e34-9d93efc5e02f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00961896","created_at":"2021-01-18T03:44:42.115Z","updated_at":"2024-07-02T16:37:36.265Z","phase":"Phase 2","brief_title":"A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients","source_id_and_acronym":"NCT00961896","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 08/01/2010","primary_completion_date":" 08/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2015-11-03"}]